Skip to main content

Table 1 Demographics, clinical characteristics and BAL cell yields for bronchoscopy subjects

From: Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients

 

Healthy

Asthma

Number

21

25

Sex (m/f)

10/11

13/12*

Age

38.5+/− 13.1

43.8 +/−12.0*

Age of asthma diagnosis

N/A

16.1 +/−16.0

Body Mass Index

25.7 +/− 3.5

27.3 +/− 3.3*

Atopy (Y/N)

1/20

21/4a

ACQ score

N/A

1.85 +/− 0.79

FEV1 % predicted

103.7+/−17.2

72.4 +/− 15.5***

FEV1/FVC

78.8 +/−5.4

65.8 +/− 10.4***

Reversibility (%)

3.2 +/− 2.6

18.9 +/− 17.4**

SABA (y/n)

0/21

24/1a

LABA (y/n)

0/21

21/4a

ICS (y/n)

0/21

25/0**

Beclomethasone dose (μg/day)

0

1125+/− 558

BAL cell yields (×106/ml BAL)

0.099 +/− 0.038

0.107 +/−0.072*

  1. Data is presented as mean +/− standard deviation. Comparisons between groups were by T-test: *p > 0.05; **p < 0.01; ***p < 0.001, or by Chi-square test: a p < 0.001
  2. Abbreviations: ACQ asthma control questionnaire, FEV 1 Forced expiratory volume in one second, FVC forced vital capacity, SABA short acting β-agonist, LABA long acting β-agonist, ICS inhaled corticosteroid; N/A not applicable